Polyamine measurements in the uterine cervix

Journal of Cellular Biochemistry

Volumn 67, Issue SUPPL. 28/29, 1997, Pages 125-132

  Mitchell, Michele Follen ^a,b   Tortolero Luna, Guillermo ^a   Lee, J Jack ^a   Hittelman, Walter K ^a   Lotan, Reuben ^a   Wharton, J Taylor ^a   Hong, Waun K ^a   Nishioka, Kenji ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

difluoromethylornithine (DFMO); Cervical intraepithelial neoplasia (CIN); Chemoprevention; Surrogate endpoint biomarker (SEB)

Indexed keywords

BIOLOGICAL MARKER; EFLORNITHINE; ORNITHINE DECARBOXYLASE INHIBITOR; POLYAMINE; PUTRESCINE; SPERMIDINE; SPERMINE; SUICIDE SUBSTRATE;

ADULT; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYAMINE SYNTHESIS; PRIORITY JOURNAL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; COHORT ANALYSIS; METABOLISM; RISK FACTOR; UTERINE CERVIX;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COHORT STUDIES; EFLORNITHINE; FEMALE; HUMANS; POLYAMINES; RISK FACTORS;

EID: 0031401653     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(1997)28/29+<125::AID-JCB14>3.0.CO;2-G     Document Type: Article

References (54)

1. Parkin DM, Pisani P, Ferlay J (1993): Estimates of the worldwide incidence of eighteen major cancers in 1985. Intl J Cancer 54:594-606.
2. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH (1994): Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 271:1866-1869.
3. American Cancer Society. "Cancer Facts and Figures." Atlanta, GA, 1996.
4. American Cancer Society. "Cancer Facts and Figures." Atlanta, GA, 1995.
5. American Cancer Society. "Cancer Facts and Figures." Atlanta, GA, 1994.
6. American Cancer Society. "Cancer Facts and Figures." Atlanta, GA, 1993.
7. (1991): A report from the CDC on four studies in New York City: The risk for cervical disease in HIV-infected women. Prim Care 11:51-52.
8. Bosch, FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995): Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 87:796-802.
9. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Doody LA (1994): Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J Cell Biochem Suppl 19:1-9.
10. Daly MB (1993): The chemoprevention of cancer: Directions for the future. Cancer Epidemiol Biomarkers Prev 2:509-512.
11. Sporn MB (1993): Chemoprevention of cancer. Lancet 342:1211-1213.
12. Boone CW, Kelloff GJ, Malone WE (1990): Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review. Cancer Res 50:2-9.
13. Verma AK, Boutwell RK (1987): Inhibition of carcinogenesis by inhibitors of putrescine biosynthesis. In McCann PP, PeggAE, SjoerdsmaA(eds): "Inhibition of Polyamine Metabolism, Biological Significance and Basis for New Therapies." Orlando, FL: Academic Press, pp 249-258.
14. Auvinen M, Paasinen A, Andersson LC, Holtta E (1992): Ornithine decarboxylase activity is critical for cell transformation. Nature 360:355-358.
15. Harris WB, Grossie VB, Ota DM, Nishioka K, Ajani JA, Chang T, Patenia D (1985): Effect of difluoromethylornithine on host and tumor polyamine metabolism during total parenteral nutrition. J Surg Res 38:592-598.
16. Grove J, Fozard JR, Mamont PS (1981): Assay of α-difluoromethylornighine in body fluids and tissues by automatic amino-acid analysis. J Chromatogr 223: 409-415.
17. Meyskens FL Jr, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspahr J, Alberts DS, Gerner EW (1994): Dose de-escalation chemoprention trial of α-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 86:1122-1130.
18. Mitchell MF, Hittelman WN, Hong WK, Lotan R, Schottenfeld D (1991): The natural history of cervical intraepithelial neoplasia: An argument for intermediate endpoint biomarkers. Cancer Epidemiol Biomarkers Prev 3:619-626.
19. Mitchell MF, Hittelman WN, Lotan R, Nishioka K, Tortolero-Luna G, Richards-Kortum R, Wharton JT, Hong WK (1995): Chemoprevention trials and surrogate endpoint biomarkers in the cervix. Cancer 76: 1956-1977.
20. Meyskens FL, Surwit EA, Moon TE, Childers JM, Davis JR, Dorr RT, Johnson CS, Alberts DS (1994): Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial. J Natl Cancer Inst 86:539-543.
21. Takami H, Romsdahl MM, Nishioka K (1979): Polyamines in blood-cells as a cancer marker. Lancet 21: 912-913.
22. Takami H, Nishioka K (1980): Raised polyamines in erythrocytes from melanoma-bearing mice and patients with solid tumours. Br J Cancer 41:751-756.
23. Loser C, Folsch UR, Paprotny C, Creutzfeldt AW (1990): Polyamines in colorectal cancer: Evaluation of polyamine concentrations in the colon tissue, serum, and urine of 50 patients with colorectal cancer. Cancer 65:958-966.
24. Nishioka K, Ezaki K, Hart JS (1980): A preliminary study of polyamines in the bone-marrow plasma of adult patients with leukemia. Clin Chim Acta 107: 59-66.
25. Russell DH (1971): Increased polyamine concentrations in the urine of human cancer patients. Nature New Biol 233:144-145.
26. Dimery IW, Nishioka K, Grossie VB Jr, Ota DM, Schantz SP, Byers R, Robbins KT, Hong WK (1987): Polyamine metabolism in carcinoma of the oral cavity compared with adjacent and normal oral mucosa. Am J Surg 154:429-433.
27. Upp JR, Saydjari R, Townsend CM, Singh P, Barranco SC, Thompson JC (1988): Polyamine levels and gastrin receptors in colon cancers. Ann Surg 207:662-669.
28. Hixson LJ, Garewal HS, McGee DL, Sloan D, Fennerty MB, Sampliner RE, Gerner, EW (1993): Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol Biomarkers Prev 2:369-374.
29. Gray MR, Wallace HM, Goulding H, Hoffman J, Kenyon WE, Kingsnorth AN (1993): Mucosal polyamine metabolism in the columnar-lined oesophagus. Gut 34:584-587.
30. Kingsnorth AN, King WWK, Diekema KA, McCann PP, Ross JS, Malt RA (1983): Inhibition of ornithine decarboxylase with 2-difluoromethylornithine: Reduced incidence of dimethylhydrazine-induced colon tumors in mice. Cancer Res 43:2545-2549.
31. Koo HB, Sigurdson ER, Daly JM, Berenson M, Groshen S, Decosse JJ (1988): Ornithine decarboxylase levels in human colorectal neoplasia. J Surg Oncol 38:240-243.
32. LaMuraglia GM, Lacaine F, Malt RA (1986): High ornithine decarboxylase activity and polyamine levels in human colorectal neoplasia. Ann Surg 204:89-93.
33. Moorehead RJ, Hoper M, McKelvey STD (1987): Assessment of ornithine decarboxylase activity in rectal mucosa as a marker for colorectal adenomas and carcinomas. Br J Surg 74:364-365.
34. Narisawa T, Takahashi M, Niwa M, Koyama H, Kotanagi H, Kusaka N, Yamazaki Y, Nagasawa O, Koyama K, Wakizaka A, Fukaura Y (1989): Increased mucosal ornithine decarboxylase activity in large bowel with multiple tumors, adenocarcinoma, and adenoma. Cancer 63:1572-1576.
35. Porter CW, Herrera-Ornelas L, Pera P, Petrelli NF, Mittelman A (1987): Polyamine biosynthetic activity in normal and neoplastic human colorectal tissues. Cancer 60:1275-1281.
36. Nishioka K, Grossie VB, Chang TH, Ajani JA, Ota DM (1991): Colorectal ornithine decarboxylase activity in human mucosa and tumors: Elevation of enzymatic activity in distal mucosa. J Surg Oncol 47:117-120.
37. Berdinskikh NK, Ignatenko NA, Zaletok SP, Ganina KP, Chorniy VA (1991): Ornithine decarboxylase activity and polyamine content in adenocarcinomas of human stomach and large intestine. Intl J Cancer 47:496-498.
38. Nishioka K, Romsdahl MM (1974): Elevation of putrescine and spermidine in sera of patients with solid tumors. Clin Chim Acta 57:155-161.
39. Nishioka K, Romsdahl MM (1977): Preliminary longitudinal studies of serum polyamines in patients with colorectal carcinoma. Cancer Lett 3:197-202.
40. Nishioka K, Romsdahl MM, McMurtrey MJ (1977): Serum polyamine alterations in surgical patients with colorectal carcinoma. J Surg Oncol 9:555-562.
41. Takaue Y, Nishioka K, van Eys J (1986): Evaluation of polyamine levels in cerebrospinal fluid of children with brain tumors. J Neurooncol 3:327-333.
42. McGarrity TJ, Peiffer LP, Bartholomew MJ, Pegg AE (1990): Colonic polyamine content and ornithine decarboxylase activity as markers for adenomas. Cancer 66:1539-1543.
43. Garewal HS, Gerner E, Sampliner RE, Roe D (1988): Ornithine decarboxylase and polyamine levels in columnar upper gastrointestinal mucosa in patients with Barrett's esophagus. Cancer Res 48:3288-3291.
44. Luk GD, Baylin SB (1984): Ornithine decarboxylase as a biologic marker in familial colonic polyposis. N Engl J Med 311:80-83.
45. Garewal HS, Sampliner R, Gerner E, Steinbronn K, Alberts D, Kendall D (1988): Ornithine decarboxylase activity in Barrett's esophagus: A potential marker for dysplasia. Gastroenterology 94:819-821.
46. Arlow FL, Colarian J, Galzada R, Luk GD, Majumdar APN (1991): Differential activation of ornithine decarboxylase and tyrosine kinase in the rectal mucosa of patients with hyperplastic and adenomatous polyps. Gastroenterology 100:1528-1532.
47. Lawson MJ, White LM, Coyle MP, Butler RN, Roberts-Thomson IC, Conyers RAJ (1989): An assessment of proliferative and enzyme activity in transitional mucosa adjacent to colonic cancer. Cancer 64:1061-1066.
48. Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, Pomplun M, Wilding G (1992): Randomized phase I chemoprevention dose-seeking study of α-difluoromethylornithine. J Natl Cancer Inst 85:732-736.
49. Braverman DZ, Stankiewicz H, Goldstein R, Patz JK, Morali GA, Jacobsohn WZ (1990): Ornithine decarboxylase: An unreliable marker for the identification of population groups at risk for colonic neoplasia. Am J Gastroenterol 85:723-726.
50. Desai TK, Parikh N, Bronstein JC, Luk GD, Bull AW (1992): Failure of rectal ornithine decarboxylase to identify adenomatous polyp status. Gastroenterology 103:1562-1567.
51. Pendyala L, Creaven PJ, Porter CW (1993): Urinary and erythrocyte polyamines during the evaluation of oral α-difluoromethylornithine in a phase I chemoprevention clinical trial. Cancer Epidemiol Biomarkers Prev 2:235-241.
52. Creaven PJ, Pendyala L, Petrell NJ (1993): Evaluation of α-difluoromethylornithine as a potential chemopreventive agent: Tolerance to daily oral administration in humans. Cancer Epidemiol Biomarkers Prev 2:243-247.
53. Mitchell MF, Tortolero-Luna G, Lee JJ, Hittelman WN, Lotan R, Wharton JT, Hong WK, Nishioka K (1998): Phase I dose de-escalation trial of α-difluoromethylornithine in patients with cervical intraepithelial neoplasia grade 3. Clin Cancer Res 4:303-310.
54. Nishioka K (1996): Introduction to polyamines. In Nishioka K (ed): "Polyamines in Cancer: Basic Mechanisms and Clinical Approaches." Austin: R. G. Landes Co, p 3.